These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36185768)

  • 1. Anti‑PD‑1 immune checkpoint inhibitor inducing endocrine toxicity in a patient with advanced lung cancer: A case report and literature review.
    Bao S; Jiang X
    Exp Ther Med; 2022 Nov; 24(5):681. PubMed ID: 36185768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
    Li S; Zhang Y; Sun Z; Hu J; Fang C
    Medicine (Baltimore); 2018 Nov; 97(45):e12907. PubMed ID: 30407284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
    Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 6. Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism.
    Patel S; Chin V; Greenfield JR
    Endocrinol Diabetes Metab Case Rep; 2019 Dec; 2019():. PubMed ID: 31829972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report.
    Lopes AR; Russo A; Li AY; McCusker MG; Kroopnick JM; Scilla K; Mehra R; Rolfo C
    Transl Lung Cancer Res; 2020 Oct; 9(5):2149-2156. PubMed ID: 33209634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer.
    Cunha C; Silva E; Vieira AC; Saraiva C; Duarte S
    Endocrinol Diabetes Metab Case Rep; 2022 Feb; 2022():. PubMed ID: 35140188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab.
    Li L; Masood A; Bari S; Yavuz S; Grosbach AB
    Case Rep Oncol; 2017; 10(1):230-234. PubMed ID: 28611636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
    Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
    J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune Polyendocrinopathy Induced by an Antibody (KN046) That Simultaneously Inhibits PD-L1 and CTLA-4: A Case Report and Literature Review.
    Li M; Wu C; Liu Y; Zhang R; Yang Q; Shi Z; Sun W; Hu X
    Diabetes Metab Syndr Obes; 2022; 15():1253-1260. PubMed ID: 35494533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
    J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment.
    Mengíbar JL; Capel I; Bonfill T; Mazarico I; Espuña LC; Caixàs A; Rigla M
    Endocrinol Diabetes Metab Case Rep; 2019 Jul; 2019(1):. PubMed ID: 31310083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report.
    Porntharukchareon T; Tontivuthikul B; Sintawichai N; Srichomkwun P
    J Med Case Rep; 2020 Sep; 14(1):171. PubMed ID: 32988414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.
    Kethireddy N; Thomas S; Bindal P; Shukla P; Hegde U
    J Oncol Pharm Pract; 2021 Jan; 27(1):207-211. PubMed ID: 32390537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitor-related thyroid dysfunction.
    Iwama S; Kobayashi T; Yasuda Y; Arima H
    Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101660. PubMed ID: 35501263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.
    Presotto EM; Rastrelli G; Desideri I; Scotti V; Gunnella S; Pimpinelli N; Vaccher E; Bearz A; Di Costanzo F; Bruggia M; Mini E; Maggi M; Peri A
    J Endocrinol Invest; 2020 Mar; 43(3):337-345. PubMed ID: 31542865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
    Delasos L; Bazewicz C; Sliwinska A; Lia NL; Vredenburgh J
    J Oncol Pharm Pract; 2021 Apr; 27(3):716-721. PubMed ID: 32723064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab-induced thyroid dysfunction in patients with lung cancer.
    Ramos-Levi AM; Rogado J; Sanchez-Torres JM; Colomer R; Marazuela M
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Jan; 66(1):26-34. PubMed ID: 29910159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.